Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection
- Conditions
- Interventions
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Marc de Perrot
- Target Recruit Count
- 12
- Registration Number
- NCT06331455
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Canada
A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 54
- Registration Number
- NCT06290505
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Border Medical Oncology, Albury, New South Wales, Australia
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06287775
- Locations
- 🇺🇸
JHU Sidney Kimmel Comprehensive Cancer Center LAO, Baltimore, Maryland, United States
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT06282575
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇺🇸Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone - Ambulatory Care Center, New York, New York, United States
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Yuanquan Yang
- Target Recruit Count
- 24
- Registration Number
- NCT06263153
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 30
- Registration Number
- NCT06255262
- Locations
- 🇨🇳
Anshan Cancer Hospital, Anshan, Liaoning, China
🇨🇳The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, China
🇨🇳First Hospital of China Medical University, Shenyang, Liaoning, China
Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Arbutus Biopharma Corporation
- Registration Number
- NCT06245291
- Locations
- 🇨🇳
China Medical University Hospital, Taichung City, Taiwan
🇹🇭The Hiv Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
🇨🇳Chia-yi Christian Hospital, Chia-Yi City, Taiwan
Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Universität des Saarlandes
- Target Recruit Count
- 43
- Registration Number
- NCT06223711
- Locations
- 🇩🇪
Kliniken Maria Hilf, Mönchengladbach, NRW, Germany
🇩🇪Saarland University Medical Center and Saarland University Faculty of Medicine, Clinic for Radiotherapy and Radiooncology, Homburg, Saarland, Germany
🇩🇪University Hospital Regensburg, Clinic and Polyclinic for Radiotherapy, Regensburg, Bavaria, Germany
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 550
- Registration Number
- NCT06211036
- Locations
- 🇺🇸
Franciscan Health Indianapolis, Indianapolis, Indiana, United States
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, China
--SuPERIOR Trial--
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT06191250
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.